Nrf2—a therapeutic target for the treatment of neurodegenerative diseases

Nrf2—a therapeutic target for the treatment of neurodegenerative diseases. Delinda A. Johnson, Jeffrey A. Johnson, Free Radical Biology and Medicine, Available online 14 August 2015, Page FRBMD1500535, ISSN 0891-5849, http://dx.doi.org/10.1016/j.freeradbiomed.2015.07.147.

The brain is very sensitive to changes in redox status; thus maintaining redox homeostasis in the brain is critical for the prevention of accumulating oxidative damage. Recently, a clinical trial using RTA 408 was initiated for Friedreich’s ataxia, a neurodegenerative condition responsible for cerebellar ataxia due to impaired production of the protein frataxin leading to profound deficiencies in mitochondrial respiration (ClinicalTrials.gov Identifier NCT02255435).


 Nrf2—a therapeutic target for the treatment of neurodegenerative diseases